Our genomes are continuously under remodeling. Variations at the single-nucleotide level, named single-nucleotide polymorphisms (SNPs) when present in more than 1% of the population, drive evolution and are crucial for diversity within the population and different susceptibility to diseases. SNPs within an intergenic region at 11q13 are associated with breast cancer risk (1,2). Although until recently it was not widely accepted that variations within regions with no protein-coding potential could be associated with diseases, we are now aware that the vast majority of the genome is transcribed into non-coding RNA (ncRNA) molecules (3), which are involved in a variety of biological processes. Supporting the functional role of the non-coding transcriptome, mutations within the non-coding genome are associated with cancer and other human diseases (4). Among the ncRNAs, long ncRNAs (lncRNAs) are defined as transcripts longer than 200 nucleotides with no protein-coding potential, although recently small peptides encoded by lncRNAs have been identified (5,6). LncRNAs mainly localize in the nucleus, where they regulate gene expression and other cellular processes by interacting with the cellular macromolecules DNA, RNA, and proteins (7,8). The lncRNAs-mediated control of gene expression is achieved both at the transcriptional and at the post-transcriptional level by modulation of the chromatin status and/or by directly interacting with functional proteins or RNAs (7,8). Through each one of these mechanisms lncRNAs can control several cellular functions, including cell cycle, cell proliferation, apoptosis, and DNA damage response (DDR), all pathways which dysregulation has been associated with cancer (9). As a consequence, aberrant lncRNAs expression can drive cancer phenotypes. For example, the lncRNA HOTAIR (HOX transcript antisense RNA), which controls chromatin status by binding and targeting to chromatin the Polycomb repressive complex PRC2 (10), promotes cancer invasiveness and metastasis by reprogramming the chromatin status and, thus, altering gene expression (11). Similarly, SChLAP1 (second chromosome locus associated with prostate-1) antagonizes the genome-wide localization and regulatory functions of the SWI/SNF (SWItch/Sucrose non-fermentable) chromatin-modifying complex and contributes to prostate cancer progression (12). Another way lncRNAs control cellular processes is by directly targeting RNAs and modulating their splicing, stability, and translation. LncRNA-mediated induction of alternative splicing and following inclusion of an internal ribosome entry site is the mechanism leading to the expression of an E-cadherin repressor during epithelial-mesenchymal transition (13). In addition to binding DNA and RNA, lncRNAs can also bind proteins and modulate their function. This is the case, for example, for the lncRNAs SAMMSON (survival associated mitochondrial melanoma-specific oncogenic noncoding RNA), which affects mitochondrial function.
in a pro-oncogenic way in melanoma by interacting with the mitochondrial regulator protein p32 (14). This is also one of the ways lncRNAs control genome stability, one of the hallmarks of cancer (9). Every day thousands of lesions challenge the stability of our genomes (15). DNA double-strand breaks (DSBs) are among the most dangerous DNA lesions that, if not properly repaired, can lead to genomic instability, which is associated with cancer initiation/progression and ageing. In order to cope with DNA lesions, cells have evolved a signaling cascade named DDR, which promptly recognizes the lesions, signals their presence, and in turn promotes efficient repair or, alternatively, cell death and cellular senescence (16). DSBs are mainly repaired by simply re-joining of the two DNA ends, a process known as non-homologous end joining (NHEJ), or by homologous recombination (HR), in which homologous sequences are used as template to copy back the information missing at the damaged locus (17). Recently, RNA has been discovered as a new player in the DNA damage signaling and repair world. Small ncRNA molecules, named DDRNAs DNA (damage response RNAs) and diRNAs (damage-induced RNAs), contribute, respectively, to DNA damage signaling and repair by promoting the recruitment of DNA damage proteins to the site of damage (18,19). More recently, the generation of these small RNA molecules has been integrated in a larger picture. It has been demonstrated that RNA polymerase II can bind DNA ends of DSBs where it transcribes lncRNA molecules, named damage-induced lncRNAs (diLncRNAs). DiLncRNAs are processed to generate DDRNAs and contribute to DNA damage signaling and repair by forming a scaffold for their recruitment to the damaged DNA (20). In line with these emerging findings, nascent RNAs at DSBs located in actively transcribed genes interact with DNA damage proteins and contribute to their recruitment to the site of damage (21). Similarly, the lncRNA LINP1 (lncRNA in non-homologous end joining pathway 1) controls NHEJ mediated-DSB repair by providing a scaffold linking NHEJ proteins (22). Another example is the lncRNA DDSR1 (DNA damage-sensitive RNA1), which modulates HR-mediated repair by binding hnRPUL1, a factor already known to control DNA end resection (23), and in this way modulating BRCA1 recruitment to DSBs (24). However, DDSR1 not only contributes to genome stability by binding DNA damage proteins, but it also controls the expression of DNA damage related-genes. This is one of the major mechanisms through which lncRNAs modulate genome stability. For example, the lncRNA DINO (damage induced non-coding) contributes to the amplification of the cellular response to DNA damage by binding and stabilizing p53 and, therefore, controlling the expression of its target genes (25). Differently, lincRNAp21 modulates DNA damage response by interacting with and controlling the localization of the ribonucleoprotein hnRNP-K to promoters of p53 target genes (26). Another example is the lncRNA NORAD (ncRNA activated by DNA damage), which controls the expression of DNA repair genes by sequestering negative regulators of their expression (27). By performing RNA CaptureSeq on breast cancer cell lines, Betts and colleagues identify two lncRNAs, CUPID1 and CUPID2 (CCND1-upstream intergenic DNA repair 1 and 2), which share a bi-directional promoter and are transcribed from the breast cancer-risk locus 11q13. By chromatin conformation capture, they demonstrate that the enhancer PRE1 interacts with the predicted CUPID1 and CUPID2 bi-directional promoter and controls their expression. Importantly, two of the breast cancer associated SNPs within the cancer-risk locus 11q13 are located within the enhancer and reduce its activity on CUPID1 promoter by disrupting the enhancer/promoter interaction (Figure 1), as demonstrated by chromatin conformation capture in cells heterozygous for the cancer-risk SNP. Gene expression studies reveal that CUPID1 and CUPID2 control the expression of genes involved in several physiological processes, including DNA replication, recombination, and repair. Indeed, CUPID1 and CUPID2 depletion directs repair toward NHEJ, an error-prone pathway, while reducing HR-mediated repair (Figure 1). Accordingly, breast tumors with low CUPID1 and CUPID2 expression have an HR mutation signature and high levels of structural variants. Intriguingly, while CUPID2 is localized in the cytoplasm and in the nucleus, CUPID1 has a nuclear localization only. It cannot be excluded, therefore, that these newly identified lncRNAs not only contribute to genome stability by modulating the expression of DNA damage response proteins but could also actually localize to DNA damage sites and directly contribute to DNA damage signaling and repair.

This finding is crucial since lncRNAs are being currently used as predictors or prognostic markers for cancer and could also be valid targets for cancer therapy (25). Tremendous improvements in the RNA-targeting therapeutics field have been recently obtained. For examples, antisense oligonucleotides (ASOs), locked nucleic acids which avidly
bind their target RNA and block their function, have been successfully used for targeting mRNAs and ncRNAs involved in a variety of diseases (28). Moreover, in the future, the recently discovered CRISPR-mediated RNA targeting could also be exploited in this field (29,30). In conclusion, the identification of the IncRNAs CUPID1 and CUPID2 not only helps understanding how SNPs within the 11q13 locus are associated with cancer, but also offers additional opportunities for cancer therapy.

**Acknowledgements**

Work in Fabrizio d’Adda di Fagagna’s laboratory is supported by the Associazione Italiana per la Ricerca sul Cancro, AIRC (application 12971), Human Frontier Science Program (contract RGP 0014/2012), Cariplo Foundation (grant 2010.0818 and 2014-0812), Marie Curie Initial Training Networks [FP7 PEOPLE 2012 ITN (CodAge)], Fondazione Telethon (GGP12059), Association for International Cancer Research (AICR-Worldwide Cancer Research Rif. N. 14-1331), Progetti di Ricerca di Interesse Nazionale (PRIN) 2010–2011, the Italian Ministry of Education Universities and Research EPIGEN Project, a European Research Council advanced grant (322726) and AriSLA (project ‘DDRNA and ALS’).

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**